arrow
M

Michael A. Bookman

the gynecologic cancer intergroup
H指数:63
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting

妇科肿瘤学组关于妇科癌症试验中多样性管理的行为准则:柏林妇科肿瘤学组会议的临床指南

2026-06-260
PRE
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

实用妇科癌症临床试验:妇科癌症协作组芝加哥头脑风暴会议的声明与路线图

2026-06-230
OAAI
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared to chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): Ancillary analysis of a placebo-controlled, phase 3 randomized trial

veliparib与卡铂/紫杉醇相比单化疗在 newly diagnosed ovarian cancer 患者中的质量调整无进展生存分析(VELIA/GOG3005):一项安慰剂对照、III期随机试验的附属分析

2025-11-210
PRE
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results

Veliparib联合一线化疗及作为卵巢癌的维持治疗:最终总生存期及疾病相关症状结果

2025-06-170
PRE
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2023-01-0318
OAAI
Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease (vol 140, pg 341, 2020)
2021-05-040
OAAI
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
2020-09-0127
OAAI
Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
2020-09-012
OAAI
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
2019-12-19655
OAAI
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer

铂类敏感复发性卵巢癌患者二次肿瘤细胞减灭术的疗效

2019-12-0121
PREAI
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
2019-02-0135
OAAI
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
2017-01-0121
OAAI
What is the Role of Retroperitoneal Exploration in Optimally Debulked Stage IIIC Epithelial Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Ancillary Data Study
CANCER
IF5.1
2016-11-1611
OAAI